Chair of the Research and Development Committee
Dr. Lundberg joined the Board of Ferring in January 2021 as a non-executive director and Chair of the Research and Development Committee. When Dr. Lundberg joined Ferring, he had 18 years’ leadership experience with global organisations such as AstraZeneca and Eli Lilly, and supervised the development of more than 200 drug candidates and 25 approved products across multiple therapeutic areas. He has also served on the boards of several biotechnology companies and on governmental committees in the EU and US. Dr. Lundberg has both a medical and scientific background, and before joining industry was Professor of Pharmacology at the Karolinska Institutet in Sweden.
